Cargando…
Efficacy and Gut Dysbiosis of Gentamicin-Intercalated Smectite as a New Therapeutic Agent against Helicobacter pylori in a Mouse Model
Helicobacter pylori eradication rate with conventional standard therapy is decreasing owing to antibiotic resistance, necessitating novel antibacterial strategies against H. pylori. We evaluated the efficacy of a gentamicin-intercalated smectite hybrid (S-GM)-based treatment and analyzed fecal micro...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7460432/ https://www.ncbi.nlm.nih.gov/pubmed/32785101 http://dx.doi.org/10.3390/antibiotics9080502 |
_version_ | 1783576600168628224 |
---|---|
author | Jeong, Su Jin Lee, Kyoung Hwa Kim, Jie-Hyun Park, Soon Young Song, Young Goo |
author_facet | Jeong, Su Jin Lee, Kyoung Hwa Kim, Jie-Hyun Park, Soon Young Song, Young Goo |
author_sort | Jeong, Su Jin |
collection | PubMed |
description | Helicobacter pylori eradication rate with conventional standard therapy is decreasing owing to antibiotic resistance, necessitating novel antibacterial strategies against H. pylori. We evaluated the efficacy of a gentamicin-intercalated smectite hybrid (S-GM)-based treatment and analyzed fecal microbiome composition in H. pylori-infected mice. To evaluate anti-H. pylori efficacy, mice were divided into eight groups, and H. pylori eradication was assessed by a Campylobacter-like organism (CLO) test and PCR assay of H. pylori in gastric mucosa. One week after H. pylori eradication, pro-inflammatory cytokine levels and atrophic changes in gastric mucosa were examined. Stool specimens were collected and analyzed for microbiome changes. The S-GM-based triple regimen decreased bacterial burden in vivo, compared with that in untreated mice or mice treated with other regimens. The therapeutic reactions in the CLO test from gastric mucosa were both 90% in the standard triple therapy and S-GM therapy group, respectively. Those of H. pylori PCR in mouse gastric mucosa were significantly lower in standard triple therapy and S-GM therapy groups than in the non-treatment group. Toxicity test results showed that S-GM therapy reduced IL-8 level and atrophic changes in gastric mucosa. Stool microbiome analysis revealed that compared with mice treated with the standard triple therapy, mice treated with the S-GM therapy showed microbiome diversity and abundant microorganisms at the phylum level. Our results suggested that S-GM is a promising and effective therapeutic agent against H. pylori infection. |
format | Online Article Text |
id | pubmed-7460432 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-74604322020-09-03 Efficacy and Gut Dysbiosis of Gentamicin-Intercalated Smectite as a New Therapeutic Agent against Helicobacter pylori in a Mouse Model Jeong, Su Jin Lee, Kyoung Hwa Kim, Jie-Hyun Park, Soon Young Song, Young Goo Antibiotics (Basel) Article Helicobacter pylori eradication rate with conventional standard therapy is decreasing owing to antibiotic resistance, necessitating novel antibacterial strategies against H. pylori. We evaluated the efficacy of a gentamicin-intercalated smectite hybrid (S-GM)-based treatment and analyzed fecal microbiome composition in H. pylori-infected mice. To evaluate anti-H. pylori efficacy, mice were divided into eight groups, and H. pylori eradication was assessed by a Campylobacter-like organism (CLO) test and PCR assay of H. pylori in gastric mucosa. One week after H. pylori eradication, pro-inflammatory cytokine levels and atrophic changes in gastric mucosa were examined. Stool specimens were collected and analyzed for microbiome changes. The S-GM-based triple regimen decreased bacterial burden in vivo, compared with that in untreated mice or mice treated with other regimens. The therapeutic reactions in the CLO test from gastric mucosa were both 90% in the standard triple therapy and S-GM therapy group, respectively. Those of H. pylori PCR in mouse gastric mucosa were significantly lower in standard triple therapy and S-GM therapy groups than in the non-treatment group. Toxicity test results showed that S-GM therapy reduced IL-8 level and atrophic changes in gastric mucosa. Stool microbiome analysis revealed that compared with mice treated with the standard triple therapy, mice treated with the S-GM therapy showed microbiome diversity and abundant microorganisms at the phylum level. Our results suggested that S-GM is a promising and effective therapeutic agent against H. pylori infection. MDPI 2020-08-10 /pmc/articles/PMC7460432/ /pubmed/32785101 http://dx.doi.org/10.3390/antibiotics9080502 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Jeong, Su Jin Lee, Kyoung Hwa Kim, Jie-Hyun Park, Soon Young Song, Young Goo Efficacy and Gut Dysbiosis of Gentamicin-Intercalated Smectite as a New Therapeutic Agent against Helicobacter pylori in a Mouse Model |
title | Efficacy and Gut Dysbiosis of Gentamicin-Intercalated Smectite as a New Therapeutic Agent against Helicobacter pylori in a Mouse Model |
title_full | Efficacy and Gut Dysbiosis of Gentamicin-Intercalated Smectite as a New Therapeutic Agent against Helicobacter pylori in a Mouse Model |
title_fullStr | Efficacy and Gut Dysbiosis of Gentamicin-Intercalated Smectite as a New Therapeutic Agent against Helicobacter pylori in a Mouse Model |
title_full_unstemmed | Efficacy and Gut Dysbiosis of Gentamicin-Intercalated Smectite as a New Therapeutic Agent against Helicobacter pylori in a Mouse Model |
title_short | Efficacy and Gut Dysbiosis of Gentamicin-Intercalated Smectite as a New Therapeutic Agent against Helicobacter pylori in a Mouse Model |
title_sort | efficacy and gut dysbiosis of gentamicin-intercalated smectite as a new therapeutic agent against helicobacter pylori in a mouse model |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7460432/ https://www.ncbi.nlm.nih.gov/pubmed/32785101 http://dx.doi.org/10.3390/antibiotics9080502 |
work_keys_str_mv | AT jeongsujin efficacyandgutdysbiosisofgentamicinintercalatedsmectiteasanewtherapeuticagentagainsthelicobacterpyloriinamousemodel AT leekyounghwa efficacyandgutdysbiosisofgentamicinintercalatedsmectiteasanewtherapeuticagentagainsthelicobacterpyloriinamousemodel AT kimjiehyun efficacyandgutdysbiosisofgentamicinintercalatedsmectiteasanewtherapeuticagentagainsthelicobacterpyloriinamousemodel AT parksoonyoung efficacyandgutdysbiosisofgentamicinintercalatedsmectiteasanewtherapeuticagentagainsthelicobacterpyloriinamousemodel AT songyounggoo efficacyandgutdysbiosisofgentamicinintercalatedsmectiteasanewtherapeuticagentagainsthelicobacterpyloriinamousemodel |